{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:59:38Z","timestamp":1779386378816,"version":"3.53.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41417-025-00925-5","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:43:15Z","timestamp":1756896195000},"page":"1245-1258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting MTPN sensitizes pancreatic cancer of wild-type BRCA1\/2 to Cisplatin-based chemotherapy"],"prefix":"10.1038","volume":"32","author":[{"given":"Zhuoxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-5686","authenticated-orcid":false,"given":"Xinyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-0948","authenticated-orcid":false,"given":"Yixun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-7587","authenticated-orcid":false,"given":"Berik","family":"Kouken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5172-9932","authenticated-orcid":false,"given":"Lifu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"925_CR1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"925_CR2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jamcollsurg.2021.02.020","volume":"233","author":"AK Arrington","year":"2021","unstructured":"Arrington AK, Hsu CH, Schaefer KL, O\u2019Grady CL, Khreiss M, Riall TS. Survival after margin-positive resection in the era of modern chemotherapy for pancreatic cancer: do patients still benefit? J Am Coll Surg. 2021;233:100\u20139.","journal-title":"J Am Coll Surg"},{"key":"925_CR3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncr.10757","volume":"95","author":"PA Philip","year":"2002","unstructured":"Philip PA. Gemcitabine and platinum combinations in pancreatic cancer. Cancer. 2002;95:908\u201311.","journal-title":"Cancer"},{"key":"925_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","volume":"102","author":"GY Ho","year":"2016","unstructured":"Ho GY, Woodward N, Coward JI. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 2016;102:37\u201346.","journal-title":"Crit Rev Oncol Hematol"},{"key":"925_CR5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/PL00000762","volume":"57","author":"P Jordan","year":"2000","unstructured":"Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 2000;57:1229\u201335.","journal-title":"Cell Mol Life Sci"},{"key":"925_CR6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","volume":"411","author":"JH Hoeijmakers","year":"2001","unstructured":"Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366\u201374.","journal-title":"Nature"},{"key":"925_CR7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 Mutation. J Clin Oncol. 2020;38:1378\u201388.","journal-title":"J Clin Oncol"},{"key":"925_CR8","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1158\/1078-0432.CCR-07-4953","volume":"14","author":"B Evers","year":"2008","unstructured":"Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14:3916\u201325.","journal-title":"Clin Cancer Res"},{"key":"925_CR9","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105:17079\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"925_CR10","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1074\/jbc.C000276200","volume":"275","author":"A Bhattacharyya","year":"2000","unstructured":"Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000;275:23899\u2013903.","journal-title":"J Biol Chem"},{"key":"925_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ijc.31292","volume":"143","author":"T Golan","year":"2018","unstructured":"Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, et al. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer. 2018;143:179\u201383.","journal-title":"Int J Cancer"},{"key":"925_CR12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/gut.2006.101220","volume":"56","author":"JB Greer","year":"2007","unstructured":"Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007;56:601\u20135.","journal-title":"Gut"},{"key":"925_CR13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for germline BRCA-Mutated metastatic pancreatic cancer. N. Engl J Med. 2019;381:317\u201327.","journal-title":"N. Engl J Med"},{"key":"925_CR14","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.","journal-title":"Mol Cancer"},{"key":"925_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.drup.2005.04.006","volume":"8","author":"V Brabec","year":"2005","unstructured":"Brabec V, Kasparkova J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat. 2005;8:131\u201346.","journal-title":"Drug Resist Updat"},{"key":"925_CR16","volume":"184","author":"W Wu","year":"2022","unstructured":"Wu W, Xue X, Chen Y, Zheng N, Wang J. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. Pharm Res. 2022;184:106456.","journal-title":"Pharm Res"},{"key":"925_CR17","doi-asserted-by":"crossref","first-page":"16635","DOI":"10.1016\/S0021-9258(17)46269-7","volume":"265","author":"S Sen","year":"1990","unstructured":"Sen S, Kundu G, Mekhail N, Castel J, Misono K, Healy B. Myotrophin: purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J Biol Chem. 1990;265:16635\u201343.","journal-title":"J Biol Chem"},{"key":"925_CR18","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1074\/jbc.271.5.2812","volume":"271","author":"N Sivasubramanian","year":"1996","unstructured":"Sivasubramanian N, Adhikary G, Sil PC, Sen S. Cardiac myotrophin exhibits rel\/NF-kappa B interacting activity in vitro. J Biol Chem. 1996;271:2812\u20136.","journal-title":"J Biol Chem"},{"key":"925_CR19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1083\/jcb.200207149","volume":"159","author":"S Gupta","year":"2002","unstructured":"Gupta S, Purcell NH, Lin A, Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol. 2002;159:1019\u201328.","journal-title":"J Cell Biol"},{"key":"925_CR20","volume":"9","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang H, Zhang J, Bing Z, Wang Y, Li Q, et al. Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study. PeerJ. 2021;9:e11350.","journal-title":"PeerJ"},{"key":"925_CR21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s13402-021-00610-3","volume":"44","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang W, Chen L, Chen W, Xu S, Tang L, et al. The ATO\/miRNA-885-5p\/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma. Cell Oncol. 2021;44:907\u201316.","journal-title":"Cell Oncol"},{"key":"925_CR22","doi-asserted-by":"crossref","first-page":"D1328","DOI":"10.1093\/nar\/gkae883","volume":"53","author":"AP Davis","year":"2025","unstructured":"Davis AP, Wiegers TC, Sciaky D, Barkalow F, Strong M, Wyatt B, et al. Comparative Toxicogenomics Database\u2019s 20th anniversary: update 2025. Nucleic Acids Res. 2025;53:D1328\u2013d1334.","journal-title":"Nucleic Acids Res"},{"key":"925_CR23","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52:D1265\u2013d1275.","journal-title":"Nucleic Acids Res"},{"key":"925_CR24","doi-asserted-by":"crossref","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","volume":"53","author":"S Kim","year":"2025","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2025 update. Nucleic Acids Res. 2025;53:D1516\u2013d1525.","journal-title":"Nucleic Acids Res"},{"key":"925_CR25","doi-asserted-by":"crossref","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","volume":"44","author":"D Szklarczyk","year":"2016","unstructured":"Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44:D380\u20134.","journal-title":"Nucleic Acids Res"},{"key":"925_CR26","first-page":"D845","volume":"48","author":"J Pi\u00f1ero","year":"2020","unstructured":"Pi\u00f1ero J, Ram\u00edrez-Anguita JM, Sa\u00fcch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48:D845\u2013d855.","journal-title":"Nucleic Acids Res"},{"key":"925_CR27","doi-asserted-by":"crossref","unstructured":"Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (2017);2017:bax028","DOI":"10.1093\/database\/bax028"},{"key":"925_CR28","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"key":"925_CR29","first-page":"146","volume":"20","author":"X Liu","year":"2020","unstructured":"Liu X, Li T, Huang X, Wu W, Li J, Wei L, et al. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt\/GSK3beta\/Snail pathway. Oncol Lett. 2020;20:146.","journal-title":"Oncol Lett"},{"key":"925_CR30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469\u201383.","journal-title":"Cancer Cell"},{"key":"925_CR31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2013.07.010","volume":"339","author":"R Shen","year":"2013","unstructured":"Shen R, Wang Q, Cheng S, Liu T, Jiang H, Zhu J, et al. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Cancer Lett. 2013;339:135\u201343.","journal-title":"Cancer Lett"},{"key":"925_CR32","doi-asserted-by":"crossref","first-page":"D93","DOI":"10.1093\/nar\/gkz881","volume":"48","author":"C Feng","year":"2020","unstructured":"Feng C, Song C, Liu Y, Qian F, Gao Y, Ning Z, et al. KnockTF: a comprehensive human gene expression profile database with knockdown\/knockout of transcription factors. Nucleic Acids Res. 2020;48:D93\u2013d100.","journal-title":"Nucleic Acids Res"},{"key":"925_CR33","doi-asserted-by":"crossref","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","volume":"46","author":"H Han","year":"2018","unstructured":"Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46:D380\u2013d386.","journal-title":"Nucleic Acids Res"},{"key":"925_CR34","doi-asserted-by":"crossref","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57\u201374.","DOI":"10.1038\/nature11247"},{"key":"925_CR35","doi-asserted-by":"crossref","first-page":"D1016","DOI":"10.1093\/nar\/gkae1080","volume":"53","author":"I Diamant","year":"2025","unstructured":"Diamant I, Clarke DJB, Evangelista JE, Lingam N, Ma\u2019ayan A. Harmonizome 3.0: integrated knowledge about genes and proteins from diverse multi-omics resources. Nucleic Acids Res. 2025;53:D1016\u2013D1028.","journal-title":"Nucleic Acids Res"},{"key":"925_CR36","doi-asserted-by":"crossref","unstructured":"Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database. 2016;2016:baw100.","DOI":"10.1093\/database\/baw100"},{"key":"925_CR37","doi-asserted-by":"crossref","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47:W212\u2013w224.","journal-title":"Nucleic Acids Res"},{"key":"925_CR38","doi-asserted-by":"crossref","first-page":"D100","DOI":"10.1093\/nar\/gky1128","volume":"47","author":"I Yevshin","year":"2019","unstructured":"Yevshin I, Sharipov R, Kolmykov S, Kondrakhin Y, Kolpakov F. GTRD: a database on gene transcription regulation-2019 update. Nucleic Acids Res. 2019;47:D100\u2013d105.","journal-title":"Nucleic Acids Res"},{"key":"925_CR39","doi-asserted-by":"crossref","first-page":"W45","DOI":"10.1093\/nar\/gkae358","volume":"52","author":"Z Zou","year":"2024","unstructured":"Zou Z, Ohta T, Oki S. ChIP-Atlas 3.0: a data-mining suite to explore chromosome architecture together with large-scale regulome data. Nucleic Acids Res. 2024;52:W45\u2013w53.","journal-title":"Nucleic Acids Res"},{"key":"925_CR40","doi-asserted-by":"crossref","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52:D174\u2013d182.","journal-title":"Nucleic Acids Res"},{"key":"925_CR41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gpb.2019.09.006","volume":"18","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Liu W, Zhang HM, Xie GY, Miao YR, Xia M, et al. hTFtarget: a comprehensive database for regulations of human transcription factors and their targets. Genom Proteom Bioinform. 2020;18:120\u20138.","journal-title":"Genom Proteom Bioinform"},{"key":"925_CR42","volume":"16","author":"P Zhou","year":"2017","unstructured":"Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu Y, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol Cancer. 2017;16:52.","journal-title":"Mol Cancer"},{"key":"925_CR43","volume":"53","author":"T Li","year":"2020","unstructured":"Li T, Liu X, Xu B, Wu W, Zang Y, Li J, et al. SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells. Cell Prolif. 2020;53:e12799.","journal-title":"Cell Prolif"},{"key":"925_CR44","volume":"22","author":"B Zhao","year":"2022","unstructured":"Zhao B, Qin C, Li Z, Wang Y, Li T, Cao H, et al. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs. Cancer Cell Int. 2022;22:374.","journal-title":"Cancer Cell Int"},{"key":"925_CR45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2015.04.003","volume":"364","author":"AZ Andrei","year":"2015","unstructured":"Andrei AZ, Hall A, Smith AL, Bascunana C, Malina A, Connor A, et al. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1\/2 inhibitor BMN 673. Cancer Lett. 2015;364:8\u201316.","journal-title":"Cancer Lett"},{"key":"925_CR46","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116\u201320.","journal-title":"Nature"},{"key":"925_CR47","volume":"1875","author":"S Yu","year":"2021","unstructured":"Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: roadmap to its reversal. Biochim Biophys Acta Rev Cancer. 2021;1875:188461.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"925_CR48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.21.01589","volume":"40","author":"JE Chaft","year":"2022","unstructured":"Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022;40:546\u201355.","journal-title":"J Clin Oncol"},{"key":"925_CR49","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","volume":"21","author":"ES Christenson","year":"2020","unstructured":"Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135\u2013e145.","journal-title":"Lancet Oncol"},{"key":"925_CR50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","volume":"70","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simoes C, Wiesmuller L, et al. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70:606\u201317.","journal-title":"Gut"},{"key":"925_CR51","doi-asserted-by":"crossref","first-page":"23477","DOI":"10.1074\/jbc.M313709200","volume":"279","author":"S Mabuchi","year":"2004","unstructured":"Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem. 2004;279:23477\u201385.","journal-title":"J Biol Chem"},{"key":"925_CR52","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","volume":"21","author":"CK Lee","year":"2003","unstructured":"Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21:2732\u20139.","journal-title":"J Clin Oncol"},{"key":"925_CR53","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1158\/1078-0432.CCR-06-1844","volume":"13","author":"H Biliran Jr.","year":"2007","unstructured":"Biliran H Jr., Banerjee S, Thakur A, Sarkar FH, Bollig A, Ahmed F, et al. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin Cancer Res. 2007;13:2811\u201321.","journal-title":"Clin Cancer Res"},{"key":"925_CR54","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.4049\/jimmunol.177.7.4907","volume":"177","author":"Z Xiong","year":"2006","unstructured":"Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, et al. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol. 2006;177:4907\u201316.","journal-title":"J Immunol"},{"key":"925_CR55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13046-021-01921-x","volume":"40","author":"G Carra","year":"2021","unstructured":"Carra G, Ermondi G, Riganti C, Righi L, Caron G, Menga A, et al. IkappaBalpha targeting promotes oxidative stress-dependent cell death. J Exp Clin Cancer Res. 2021;40:136.","journal-title":"J Exp Clin Cancer Res"},{"key":"925_CR56","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1101\/gad.195248.112","volume":"26","author":"H Kim","year":"2012","unstructured":"Kim H, D\u2019Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia\/BRCA pathway. Genes Dev. 2012;26:1393\u2013408.","journal-title":"Genes Dev"},{"key":"925_CR57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382\u20137.","journal-title":"Nature"},{"key":"925_CR58","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-09-2616","volume":"69","author":"DN Yarde","year":"2009","unstructured":"Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, et al. Targeting the Fanconi anemia\/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009;69:9367\u201375.","journal-title":"Cancer Res"},{"key":"925_CR59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/nar\/gkr687","volume":"40","author":"M Volcic","year":"2012","unstructured":"Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S, et al. NF-kappaB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res. 2012;40:181\u201395.","journal-title":"Nucleic Acids Res"},{"key":"925_CR60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41416-022-01823-5","volume":"127","author":"M Cremona","year":"2022","unstructured":"Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, et al. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors. Br J Cancer. 2022;127:488\u201399.","journal-title":"Br J Cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00925-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T23:03:35Z","timestamp":1763334215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00925-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00925-5","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Data from the TCGA and GTEx databases were used in our study. Our research involves human tissues derived from tumor and adjacent normal tissues of PC patients. All patients signed an informed consent form. Ethical approval for this study was obtained from the Ethical Committee of Medical Research. There are no clinical trials or animal experiments in our research. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement and consent to participate"}},{"value":"All authors agree to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}